Advertisement

Septic Shock

  • R. C. Bone
Chapter
Part of the Developments in Critical Care Medicine and Anesthesiology book series (DCCA, volume 25)

Abstract

Sepsis can be defined as the systemic response to the presence in the body of microorganisms or their toxie products. Previous clinical studies have required in vitro laboratory growth of the organisms to confirm the diagnosis of sepsis. The septic syndrome is defined by specific clinical criteria and has a significant mortality rate in addition to other sequelae commonly associated with sepsis.

Keywords

Septic Shock Adult Respiratory Distress Syndrome Sepsis Syndrome Plasma Fibronectin Bacteremic Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    McCabe W.R.: Gram negative bacteremia: Disease-a-month. Chicago, Year Book Medical Publishers, 1973.Google Scholar
  2. 2.
    Sheagren J.H.: Shock syndromes related to sepsis. Cecil Textbook of Medicine. WB Saunders, Philadelphia, 1986, pp. 1473–77Google Scholar
  3. 3.
    McCabe W.R., Treadwell T.L., Maria A.D.: Pathophysiology of bacteremia. Am J Med 75:7–18, 1983PubMedCrossRefGoogle Scholar
  4. 4.
    National Heart, Lung, and Blood Institute. Extracorporeal support for respiratory insufficiency: Collaborative study. National Heart, Lung, and Blood Institute, Washington, D.C., 1979Google Scholar
  5. 5.
    Goldfarb R.D., Tambolini W., Wiener S.M., et al: Canine left ventricular performance during LD50 endotoxemia. Am J Physiol 244:H370–7, 1983PubMedGoogle Scholar
  6. 6.
    Kreger B.E.W., Craven D.E., and McCabe W.R.: Gram-negative bacteremia: IV. Re-evaluation of clinical features and treatment in 612 patients. Am J Med 68:344–55, 1980PubMedCrossRefGoogle Scholar
  7. 7.
    McCabe W.R.: Serum complement levels in bacteremia due to gram negative organisms. N Engl J Med 288:21–3, 1973PubMedCrossRefGoogle Scholar
  8. 8.
    Winslow E.J., Loeb H.S., Rahimtoola S.H., et al: Hemodynamic studies and results of therapy in 50 patients with bacteremic shock. Am J Med 54:421–32, 1973PubMedCrossRefGoogle Scholar
  9. 9.
    Hook E.W., Horton C.A., Schaberg D.R.: Failure of intensive care unit support to influence mortality from pneumococcal bacteremia. J Am Med Assoc 249:1055–7,1983CrossRefGoogle Scholar
  10. 10.
    Bone R.C., Fisher C.J., Clemmer T.P., et al: The sepsis syndrome: A valid clinical entity. Crit Care Med 17:389–93, 1989PubMedCrossRefGoogle Scholar
  11. 11.
    Parker M.M., Parillo J.E.: Hemodynamics and pathogenesis. J Am Med Assoc 250:3324–7,1983CrossRefGoogle Scholar
  12. 12.
    Shubin H., Well M.H.: Bacterial shock. J Am Med Assoc 235:421–4, 1976CrossRefGoogle Scholar
  13. 13.
    Abraham E., Shoemaker W.C., Bland R.D., et al: Plasma fibronectin in medical ICU patients. Crit Care Med 11:799–803, 1983PubMedCrossRefGoogle Scholar
  14. 14.
    Halushka P.V., Reines H.D., Barrow S.E., et al: Elevated 6-ketoprostagiandin F1a in patients in septic shock. Crit Care Med 13:451–453,1985PubMedCrossRefGoogle Scholar
  15. 15.
    Reines H.D., Cook J.A., Halushka P.V., et al: Plasma thromboxane concentrations are raised in patients dying with septic shock. Lancet 2:174–5,1982PubMedCrossRefGoogle Scholar
  16. 16.
    Fourrier F., Chopin C., Wallaert B., et al: Compared evolution of plasma fibronectin and angio-converting enzyme levels in septic ARDS. Chest 87:191–5, 1985PubMedCrossRefGoogle Scholar
  17. 17.
    O’Connell M.T., Becker D.M., Steele B.W., et al: Plasma fibronectin in medical ICU patients. Crit Care Med 12:479–82, 1984PubMedCrossRefGoogle Scholar
  18. 18.
    Zinner S.H., McCabe W.R.: Effects of IgM and IgG antibody in patients with bacteremia due to gram-negative bacilli. J Infect Dis 133:37–45, 1976PubMedCrossRefGoogle Scholar
  19. 19.
    Pollack M., Huang A.I., Prescott R.K., et al: Enhanced survival in pseudomonas aeruginosa septicemia associated with high levels of circulating antibody to E. coli endotoxin core. J Clin Invest 72:1874–81, 1984.CrossRefGoogle Scholar
  20. 20.
    Girotti, M.J., Menkes E., MacDonald J.W.D., et al: Effects of immunization on cardiopulmonary alterations of gram-negative endotoxemia. J Appl Physiol 56:582–9, 1984PubMedGoogle Scholar
  21. 21.
    Ziegler E.J., McCutchan J.A., Fierer J., et al: Treatment of gram-negative bacteremia and shock with human antiserum to a mutant E. coli. N Engl J Med 307:1225–30, 1982PubMedCrossRefGoogle Scholar
  22. 22.
    Lachman E., Pitsoe S.B., Gaffin S.L.: Anti-lipopolysaccharide immunotherapy in management of septic shock of obstetric and gynecologicalorigin. Lancet 1:981–3, 1984PubMedCrossRefGoogle Scholar
  23. 23.
    Moore R.D., Smith C.R., Lietman P.S.: The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis 149:443–8, 1984PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1992

Authors and Affiliations

  • R. C. Bone

There are no affiliations available

Personalised recommendations